Article: LOS ANGELES BUSINESS JOURNAL: Lixte CEO Takes On a New Course
February 5, 2024
Article: Too much of a good thing in Nature Reviews Cancer
April 11, 2024
LIXTE Biotechnology Holdings Provides Update on Progress with Proprietary LB-100 Compound to Enhance Chemotherapy and Immunotherapy Cancer Treatments. Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers.
